EDNRA and chronic kidney disease: The mechanism of action of ETA-selective antagonists has been extensively studied and involves several haemodynamic changes, most notably an increase in renal blood flow, but only in patients with CKD and hypertension in whom ETA activity in the kidney is increased, while ETB-selective antagonists led to generally opposite effects [5].